CURRICULUM VITAE

ROBERT J. COURTNEY, M.D

BUSINESS ADDRESS:	Colorado Retina Associates, PC 255 S. Routt St, Suite 200 Lakewood, CO 80228 (Research Office Location)
MEDICAL LICENSE:	Colorado - 53928; Expiration Date 4/30/2021 Ohio -099320
NPI:	1760649024
GCP TRAINING:	CITI: 05JAN2023
COLORADO RETINA ASSOCIATES:	Since: 9/2014
BOARD CERTIFICATION:	Diplomate, American Board of Ophthalmology, 2013

EDUCATION AND TRAINING

COLLEGE:	University of Colorado, Boulder, CO B.A. Biochemistry, Minor in Chemistry Dean's List 1998 - 2002, Phi Beta Kappa Vocal Performance Tuition Scholarship 1998 - 2000
MEDICAL SCHOOL:	University of Colorado School of Medicine, Denver, CO Doctorate of Medicine, 2004 - 2008 Academic Excellence 2004 - 2006

3/16/21

Richard Whitehead Department of Pharmacology Award
Alpha Omega Alpha

INTERNSHIP: Scripps Mercy Hospital, San Diego, CA
Transitional Medicine, 2008 - 2009

RESIDENCY: Casey Eye Institute, Oregon Health & Science University
Portland, OR
Ophthalmology, 2009 - 2012
OKAP Award

FELLOWSHIP: Cole Eye Institute, Cleveland Clinic Foundation
Vitreoretinal Fellowship, 2012 - 2014
Fellow of the Year

PROFESSIONAL SOCIETIES: American Academy of Ophthalmology (2009 - present)
American Society of Retina Specialists (2013-present)
The Association for Research in Vision and Ophthalmology (2008-present)

CURRENT POSITIONS: Partner, Colorado Retina Associates, PC Denver, CO (September 2014-present)

MANUSCRIPTS

- Courtney RJ, McClintic JI, Ehlers JP. Comparison of optical coherence tomography scan patterns and clinical review strategies in neovascular age-related macular degeneration. Retina. 2015 Jul;35(7):1315-22

- Xu LT, Courtney RJ, Ehlers JP. Immunogammopathy maculopathy associated with Waldenstrom's macroglobulinemia. Ophthalmic Surg Lasers Imaging Retina. 2015 Feb;46(2):262-5

- Phan IT, Courtney RJ, Marx DP, Wilson DI, Mansoor A, Ng JD Proptosis Caused by Rhabdomyomatous Mesenchymal Hamartomata Occurring in the Orbit. Opbthal Plast Reconstr Surg. 2014 Aug 7. Epub ahead of print

- Courtney RJ, Singh RP. Spectral domain optical coherence tomography features in niacin maculopathy. Eye. 2014 May; 28(5):629-32.

- Yang P, Michaels KV, Courtney RJ, Wen Y, Greninger DA, Reznick L, Karr DJ, Wilson LB, Weleber RG, Pennesi ME. Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy. JAMA Ophthalmol. 2014 Jul; 132(7):823-31.

- Courtney RJ, Pennesi ME. Interval spectral domain optical coherence tomography and electrophysiology findings in neonatal adrenoleukodystrophy. JAMA Ophthalmol. 2013 Jun 1; 131(6):807-10.

- Pennesi ME, Neuringer M, Courtney RJ. Animal models of age-related macular degeneration. Mol Aspect Med. 2012 Jun 13.

- Courtney RJ, Pennesi ME. Inherited retinal degenerations with systemic manifestations. Int Ophthalmol Clin. 2012 Winter;52(1):11

- Courtney RJ, Pennesi ME. Retinal dystrophy in 2 brothers with a-mannosidosis. Arch Ophthalmol. 2011;139(6):7

- Courtney RJ, Lauer AK. A Comparison of local anesthesia techniques for intravitreal injections. AMD Update (available online at Ophthalmology Management). 2011 May; 51.

- Olson JL, Courtney RJ, Rouhani B, Mandava N, Dinarello CA. Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocul Immunol Inflamm. 2009 May-Jun;
  17(3):195-200.

- Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model, Arch Ophthalmol. 2007 Sep; 125(9): 1221-1224.

- Srivastava SK, Courtney RJ, Baynes K, Rennebohm RM, Lowder C. Widefield angiographic findings of Susac syndrome. Manuscript in preparation

- Bailey ST, Courtney RJ, Jones JM, Weleber RG. Pigmented paravenous retinochoroidal atrophy: hill of vision modeling and evidence for a herpes simplex etiology. Manuscript in revision

POSTERS

- Courtney RJ, Ehlers JP. An Immunogammopathy maculopathy associated with Waldenstrom ' s macroobulinernia. ASRS, Toronto, August 2013.
- Courtney RJ, Kumar P, Ehlers JP, Baynes K, Srivastava SS. Ultra-widefield angiographic findings in susac syndrome. ASRS, Toronto, August 2013.

- Courtney RJ, McClintic Ehlers JP. Comparison of optical coherence tomography scan patterns and clinical review strategies in the management of neovascular age-related macular degeneration. ARVO, Seattle, Washington, May 2013.
- Courtney R), Wen Y, Pickell SR, Weleber RG, Pennesi ME. Hand-held spectral-domain optical coherence tomography in the evaluation of pediatric patients with congenitai nystagmus. ARVO 4054, Fort Lauderdale, Florida, May 2011.
- Courtney RJ, Weleber RG, Bailey ST, Jones JM. Modeling and analysis of the hill of vision in

pigmented paravenous retinochoroidal atrophy using full-field static perimetry. ARVO 1386, Fort Lauderdale, Florida, May 2010.

- Courtney R}, Mandava N, Oliver S, Quiroz-Mercado H, Olson J. Intravitreal inhibition of choroidal neovasularization in an animal model: a comparison of infliximab, anakinra and LD22-4. ARVO, Fort Lauderdale, Florida, May 2009.
- Mandava N, Courtney RJ, Olson JL. intravitreal infliximab inhibits growth of choroidal neovascular membranes in an animal model. The Club Jules Gonin and the Retina Society, Cape Town, South Africa, October 2006.
- Olson JL, Courtney RJ, Mandava N. Intravitreal anakinra inhibits growth of choroidal neovascular membranes in an animal model. The Club Jules Gonin and the Retina Society, Cape Town, South Africa October 2006*

BOOK CHAPTERS

Courtney R), Singh RP, Aranow M, Singh AD. Ocular paraneoplastic diseases. Clinical Ophthalmic Oncology. 2nd ed. Ed. Arun Singh, Bertil Damato. New York: Springer-Verlag, 2014. 133-152. Print.

PROGRAMS/STIPENDS

NIH Summer Research Training Program (June-Aug 2005)
Pharmacologic therapy of age-related macular degeneration
University of Colorado School of Medicine, Dept. of Ophthalmology

INVITED PRESENTATIONS

- Widefield imaging (November 2013)
  Mile High Masters of Retina, Denver, Colorado

- Widefield imaging in posterior uveitis (October 2013)
  Rocky Mountain Lions Eye Institute, University of Colorado, Aurora, Colorado

- Current and emerging therapies in age-related macular degeneration (March 2011)
  Oregon Academy of Ophthalmology, Portland, Oregon

CLINICAL TRIALS

Co-Investigator: A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applie by Microvolume Injection or Infusion in Subjects with Exudative Age-Related Macular Degeneration.

Co-investigator: Prevention of Macular Edema in Patients with Diabetic Retinopathy Undergoing Cataract Surgery.

Co-Investigator: Ozurdex for Diabetic Macular Edema Treated with Pars Plana Vitrectomy and Membrane Removal.

Co-Investigator: A Single Arm, Investigator Initiated Observational Study of the Efficacy, Safety, and Tolerability of intravitreal Aflibercept Injection in Subjects with Exudative Age-Related Macular Degeneration Previously Treated with Ranibizumab or Bevacizumab.

CLINICAL TRIALS (Colorado Retina Associates):

SEATTLE (Acucela) Protocol number: 4429-202, Investigator Title: A Phase 2b/3 multicenter, randomized, double-masked, dose ranging study comparing the efficacy and safety of emixustat HCL (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry agerelated macular degeneration. 2013-2016

BAM (GSK)- investigator, Title: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo[e] controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmokinetics and Pharmacodynamics of GSK933 776 in Adult Patients with Geographic Atrophy Secondary to AgeRelated Macular Degeneration
2012-2016

FOVISTA (Ophthotech): Protocol: OPH1003- Investigator, A Phase 3, Randomized, Double•Masked,
Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of FOVISTA™ (ANTI-PEGYLATED APTAMER) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration
2014-present

FORSIGHT (Forsight, Inc)- Investigator, A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404PDS in Chronic Noninfectious Uveitis
2014-2015

ORA (Aerpio Therapeutics) Investigator, A Phase 2, Randomized, Active-Controlled, DoubleMasked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778
Administered for 3 months, as Monotherapy or Adjunctive to Ranibizumab,
In Subjects with Diabetic Macular Edema

2014-2015

TOGA (University of Virginia) Investigator, A Randomized, Double-Masked, Placebo Controlled Study Evaluating ORACEA in Subjects with Geographic Atrophy Secondary to Non-Exudative AgeRelated Macular Degeneration
2014-present

ORBIT (Thrombogenics) Protocol: TG-MV-018, Sub-investigator Ocriplasmin Research to Better Inform
2014-present

EYEGUARD (XOMA) Sub-Investigator A Randomized, Double-Masked, Placebo Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, Or Pan-Uveitis
2012-2015

EYEGUARD (XOMA) Sub-Investigator A Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious intermediate, posterior, or pan-uveitis currently controlled with systemic treatment 2012-2015

SAKURA (Santen, Inc) Sub-Investigator A Phase 111* Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of Active, Non-InfectiousUveitis of The Posterior Segment of the Eye
2012-present

STOP (Genentech, University of Nebraska): Protocol number: ML28522, Sub-Investigator Title: Study of the safety, tolerability and bioactivity of tocifizumab on patients with noninfectious uveitis 2012-present

OPTINA (Ampio Pharmaceuticals) Sub-Investigator, Title: A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema
2013-2015

OCULOS (Ohr Pharmaceuticals): Sub-Investigator, A Phase 2 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular AgeRelated Macular Degeneration
2012-2015

EMERGE (ICONIC): Protocol: IT-002, Sub-investigator. A Phase II, Randomized, Double-Masked, Multicenter, Active-Controlled Study Evaluating the Safety of Repeated Intravitreal injections ofhLconl administered as monotherapy or in combination with ranibizumab compared to ranibizumab monotherapy. 2015-present

XCOVERY (Tyrogenex): Protocol: X82-OPH-201, Sub-Investigator, A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Non-Inferiority Study of X-82 plus prn Eylea@ monotherapy in Neovascular AMD 2015-present

SPECTRI (LAMPA) (Regeneron) Sub-investigator, A Phase IIk, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration 2015-present

NEUROTECH: (Neurotech) Protocol: NT-503-3-AMD-001), Sub-investigator, A Multi-center, TwoStage, Open-Label Phase and Randomized, Active Controlled, Masked Phase il Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eyelea@ for the Treatment of Recurrent Subfoveal Choroidal Neovascularization
(CNV) Secondary to Age-Related Macular Degeneration (AMD) 2015-present

LADDER (Genentech) Protocol: GX28228, Sub-Investigator, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration 2015-present

VIDI(ASTELLAS): 8232-CL-OOI, Sub-investigator, A Phase [I, Double-Masked, Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema 2015-present

HAWK (Alcon): Protocol RTH258-C001, Sub-Investigator, A Two-year, Randomized, DoubleMasked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus
Afibercept in Subjects with Neovascular Age-Related Macular Degeneration 2015-present

CAPELLA (Regeneron): Protocol: R2176-3-AMD-1417, Sub-investigator, A Phase II, DoubleMasked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176—3 in Patients with Neovascular Age-Related Macular Degeneration 2015-present

CEDAR (Allergan): Protocol: AGN-150998, Sub-Investigator, A Multicenter, Double-Masked, Randomized 100-week, Parallel-Group, Active-Controlled Study to Evaluate the Safety and Efficacy of Abicipar in Treatment-Naive patients with Neovascular AMD.
2015-present

VAPOR (Santen): Protocol: 35-002: Sub-investigator, A Multicenter, Randomized, Open Label,

Phase lla Study Assessing the Efficacy, Safety and Duration of Effect on Intravitreal Injections of DE120 (a VEGF and PDGF Receptor Inhibitor) as Monotherapy and with a Single Eyelea@ Injection in Subjects with Treatment-Naive Exudative Age-Related Macular Degeneration. 2015-present

ALDEYRA (Aldeyra): Protocol: NS2-02, Sub-Investigator, A Phase 2, Randomized, InvestigatorMasked, Comparator Controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis
2015-present

AVENUE (Roche) Protocol: BP29647, Sub-Investigator, A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy of R06867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to AgeRelated Macular Degeneration
2015-present

PROXIMA (Genentech) Protocol: GX29633, Sub-investigator, A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
2015-present

LHA510 (Alcon/Novartis) Protocol: LHA510-2201, Sub-investigator, A Randomized, DoubleMasked, Vehicle-Controlled* Proof-of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients with Wet Age-Related Macular Degeneration. 2015-present

AURA (Aura Biosciences) Protocol: AU-011-201, Investigator, A Prospective, Randomized, MultiCenter, Masked Clinical Trial Designed to Evaluate Two Doses of Light-Activated AU-OII for the
Treatment of Subjects with Small to Medium (1.5-4.0 mm thickness) Primary Uveal Melanoma
2016-2018

PANORAMA (Regeneron) Protocol: VGFT-E-1412, Sub-Investigator, Title: A Phase 3, DoubÆe-Masked, Randomized Study of the Efficacy and Safety of Intravitrea] Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy 2015 - 2018

EXPOSURE (Genentech) Protocol: GX29455, Sub-investigator, Title: A Phase II, Multicenter, Randomized, Single-Masked, sham injection - Study of lampalizumab Intrevitreal Injections administered to patients with Geographic atrophy, 2014-2017

EYEGATE (Eyegate) Protocol: EGP-437-006, Sub-Investigator, A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-Infectious Anterior Segment Uveitis 2016-present

ABICIPAR DME Protocol: 1771-201-008, Sub-investigator, A multicenter, open-label, single-arm study to evaluate abicipar for safety and treatment effect in patients with neovascular age-related macular degeneration (AMD) 2015-2016

AERPIO/TIME2B: Sub-investigator, Phase 2 Double-masked, Placebo-Controlled Study To Assess The Safety And Efficacy Of Subcutaneously Administered AKB-9778 15mg Once Daily Or 15mg Twice Daily For 12 Months In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy 2017-2018

OLEI: Sub-investigator, A Phase II, Multicenter, Randomized, Single-Masked, sham injection - Study of lampalizumab Intrevitreal Injections administered to patients with Geographic atrophy who have completed prior Lampa Studies, 2013-2017

STAIRWAY: Sub-investigator, This is a Phase II, multicenter, randomized, active comparator-controlled, subject and outcomeassessor masked, parallel group, 52-week study to investigate the efficacy, safety, and pharmacokinetics of RO6867461 administered at 12- and 16-week intervals in treatment-naive patients with nAMD 2016-2017

TLC399A2002: Sub-investigator, A Phase Trial of TLC399 (ProDex) in Subjects with Macular Edema due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability 2016-2018

HAWK Extension (Alcon): Protocol RTH258-C001, Sub-Investigator, Title: A Two-year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Afibercept in Subjects with Neovascular Age-Related Macular Degeneration who participated in Hawk 1. 2017-2018

BOULEVARD: BP30099 Sub-Investigator, a multiple-center, multiple-dose, randomized, active comparator–controlled, double-masked, three parallel group, 36-week study in patients with CI-DME 2016-2017

IT-003: Iconic Sub-Investigator, A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-I in Patients with Uveal Melanoma Who are Planned to Undergo Enucleation or Brachytherapy 2016-2017

SAPPHIRE: CLS1003-30, Sub-Investigator, A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion 2016-present

GILEAD: Sub-Investigator, A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Noninfectious Uveitis 2018 – present

OPT-302: Sub-Investigator, A dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab in participants with wet AMD 2018 – present

OPH2003B: Sub-Investigator, A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration 2018 – present

OPH2007: Sub-Investigator, A phase 2A open label to assess the safety of Zimura (Anti-C5) administered in combination with Lucentis 0.5 mg in NVAMD 2018-present

2018- Present: GR40549: Sub-Investigator, A Multicenter, open-label extension stud to evaluate the long-term safety and tolerability of the Port Delivery System with Ranibizumab in patients with Neovascular Age-related macular denegation

2018- Present: GR40548: Sub-Investigator, A Phase III, multicenter, randomized, visual assessor-masked active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration

2018- Present: KHB-1801, Sub-investigator, A Multicenter, double-masked, randomized dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with Neovascular age-related macular degeneration

2018- present: CRTH258AUS04, Sub-Investigator, A Multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6 mg q 4 weeks compared to aflibcercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid (MERLIN)

2018-Present: 010906IN, Sub-Investigator, Lumina: A Phase III, multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of intravitreal injections of 440 µg DE-109 for the treatment of active, non-infectious Uveitis of the Posterior Segment of the Eye

2018-Present, GR40844, Sub-investigator, A phase III, multicenter, randomized double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Neovascular Age-Related Macular Degeneration (Lucerne)

2018-Present, GR40349, Sub-investigator, A Phase III, Multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab (RO6867461) in patients with Diabetic Macular Edema (Yosemite)

2018-Present, APL2-304, Sub-investigator, A Phase III, multicenter, randomized, double-masked, sham-controlled study to compare the efficacy and safety of Intravitreal APL-2 Therapy with Sham injections in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD)

2018-Present, ADVM-022-02, Blood specimen collection study for the measurement of Adeno-Associated Virus (AAV) Neutralizing Antibodies in subjects with Neovascular (Wet) Age-related macular degeneration

2018-Present, ADVM-022-01, An open label Phase 1 study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-related macular degeneration (Optic)

2019-present: Gemini, Sub-investigator, A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with Non-central Geographic Atrophy (GA) who are carriers of high-risk genetic complement variants associated with Dry Age-related Macular Degeneration (AMD)

2019- Present: KSI-CL-102, Sub-Investigator, A phase 2, prospective randomized, double-masked, active comparator controlled, multi-center study to investigate the efficacy and safety of repeated intravitreal administration of KSI-301 in subjects with Neovascular (Wet) Age-related macular degeneration

2019- Present: ONS-5010-002, A Clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in Subjects with Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

2019- Present: XBR1001, Sub-Investigator, A Phase III Double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis in Patients with Neovascular Age-Related Degeneration

2019-Present, GR40973, Sub-Investigator, A Phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of

FHTR2163 in Patients with Geographic atrophy secondary to age-related Macular Degeneration (Gallego)

2019-Present, ALK-001, Sub-Investigator, A Phase 2/3 multicenter, randomized, double-masked, parallel-group, Placebo-controlled study to investigate the safety, Pharmacokinetics, tolerability, and efficacy of ALK-001 in Geographic Atrophy secondary to age-related macular degeneration

2019-Present, GR40550, Sub-Investigator, A Phase III, Multicenter, Randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery system with Ranibizumab in patients with Diabetic Macular Edema (Pagoda)

2019- Present, VGFTe(HD)-AMD-1905, Sub-Investigator, A randomized, single-masked, active-controlled Phase 2 study of the safety, tolerability, and efficacy of repeated doses of High-dose Aflibercept in patients with Neovascular Age-Related macular degeneration.

Pavilion (Genentech), Protocol:GR41675, Sub-Investigator, A Phase III, Multicenter, Randomized, study of the efficacy, safety, and Pharmacokinectics of the port delivery system with Ranibizumab in patients with Diabetic Retinopathy. 2020-present

Infinity (Adverum), Protocol: ADVM-022, Sub-Investigator, A Phase 2, multi-center, randomized, double-masked, active controlled study of ADVM-022 (AAV.7m8-aflibercept) in subjects with Diabetic Macular Edema. 2020-present.

Regatta (Gemini Therapeutics), Protocol: GEM-CL-10302, Sub-Investigator, A Mulitcenter, Open-label, Multiple dose study in patients with Geographic Atrophy secondary to Dry Age-Related Macular degeneration to evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103. 2020-Present.

Gather2 (IVERIC), Protocol: ISEE2008, Sub-Investigator, A Phase 3 Multicenter, Randomized, Double-Masked, Sham-controlled clinical trial to assess the safety and efficacy of intravitreal administration of ZIMURA™ (Complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related macular degeneration. 2020-Present.

Amgen (Amgen, Inc), Protocol: 20170542, Sub-Investigator, A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety compared to Aflibercept (Eylea) in subjects with Neovascular age-related macular degeneration. 2020-Present.

Photon (Regeneron), Protocol: VGFTe-HD-DME-1934, Sub-Investigator, A Randomized, Double-masked, Active-controlled Phase 2/3 study of the efficacy and safety of high-dose Aflibercept in patients with Diabetic Macular Edema. 2020-Present

Rhone-X (Genentech), Protocol: GR41987, Sub-Investigator, A Multicenter, Open-Label Extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema. 2020-Present.

Catalina (NGM Bio), Protocol: NGM621-GA-201, Sub-Investigator, A Phase 2 Multicenter, Randomized, Double-masked, Sham-Controlled study of the Safety and efficacy of intravitreal injections of NGM621 in subjects with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). 2020-Present

Pagoda (Genentech), Protocol: GR40550, Sub-Investigator, A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema, 2020-present